A Phase I/II Study to Evaluate the Safety, Pharmacodynamics and Efficacy of Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma
Latest Information Update: 24 Mar 2025
At a glance
- Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Entinostat (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 20 Mar 2025 Status changed from suspended to discontinued; Genentech has closed the study due to lack of data with Atezo
- 06 Jun 2023 PreliminaryrResults presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 29 Oct 2022 Planned End Date changed from 31 Dec 2023 to 30 Jun 2024.